OBJECTIVE: To project the impact of Ezetimibe 10mg (EZ10) co-administration for typical CHD patient not attaining TC goal with simvastatin 10mg (S10) monotherapy in Finland on remaining life expectancy, mean TC reduction, and percent reaching goal. METHOD: A decision-analytic model is used to project benefits of lipid therapy. Clinical trial data on the distribution of TC changes was used to project the percent of patients reaching TC goal with ezetimibe co-administered with current statin therapy compared to titration (up to the maximum approved dose of Simvastatin 80mg) to attain goal TC. Impact of TC changes on life expectancy was projected using Framingham risk equations and non-coronary mortality rates from Statistics Finland. In the base case the model was run for a 55 year old male on treatment with S10 and having TC = 6 mmol/L, and HDL = 1.1 mmol/L. The benefits were also obtained for men and women aged 35 to 75 years with TC 5.5 to 8.0 mmol/L. RESULTS: For a 55-year-old male CHD patient with TC = 6 mmol/L while on S10, Ezetimibe co-administration with simvastatin is projected to increase the remaining life expectancy from 10.8 to 11.24 years compared to statin titration where 42% not at goal are titrated at each dose (titration strategy I) and from 11.09 to 11.24 years compared to statin titration where all patients not at goal were titrated to attain goal (titration strategy II). Projected additional patients at TC goal per 100 treated and mean TC reduction are 10 and 3.66% for titration strategy I, 57 and 14.5% for titration strategy II, and 65 and 18.28% for EZ10 co-administration with S10. CONCLUSION: For the patient profile studied EZ10 co-administration with current statin is projected to bring more patients to goal and may increase survival time compared to titrating statin.